



CIN NO.: L24230WB1982PLC034492

Date: 30th July, 2022

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,


Sub: Outcome of Board Meeting held on 30th July, 2022

This is to inform you that, Pursuant to Regulation 30 & 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the meeting of Board of Directors of the Company held on **Saturday, 30th July, 2022 (which commenced at 11:00 Morning and concluded 12:15 P.M.)** wherein they have adopted / approved the following:

1. Standalone Un-Audited Financial Results for 01st quarter ended 30th June, 2022 along with Limited Review Reports, pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015-**Annexure-1**
2. 41st Annual General Meeting of the Company will be held on 12th Day of September, 2022 (Monday) at 02:00 P.M. IST through Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”).
3. Notice of 41st Annual General Meeting of the Company for the financial year ended 31st March 2022. The Notice convening the 41st AGM will be sent to the Stock Exchange in due course.
4. Approved the Board Report, Corporate Governance Report & Management Discussion Analysis Report for the financial year ended 31st March 2022.
5. A) Pursuant to Regulation 42 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, date of Closure of Share Transfer Books & Register along with Section 91 of the Companies Act, 2013 shall remain closed from Tuesday, 06/09/2022 to Monday, 12/09/2022, (Both days inclusive) for the purpose of 41st Annual General Meeting to be held on 12th September, 2022.

B) In compliance with provision of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management & Administration) Rules, 2014, as amended, the cut off date to record the entitlement of Members to cast their Votes for the businesses to be transacted at the ensuing 41st Annual General Meeting of the Company is fixed as 05/09/2022, Monday.

C) The e-voting period will be begin on Thursday, 08th September, 2022 (9:00 A.M.) and ends on Sunday, September 11, 2022 (5:00 P.M.).
6. Mr. Rahul Bhutoria, Partner M/s. B J B And Associates (F.R. No. 329621E), Practicing Chartered Accountant (Membership No. 304193) has been appointed as the Scrutinizer to the e-Voting process and remote e-voting process in a fair and transparent manner for purpose of 41st Annual General Meeting.
7. Approved Re-appointment of Mr. Shri Prakash (DIN: 007526354), a Non-Executive Director who retires by rotation in terms of Section 152, Companies Act 2013 subject to approval of Shareholders in the ensuing Annual General Meeting.



Email:investors@adinathbio.com
Website:www.adinathbio.com

4, Netaji Subhas Road, 1st Floor, Kolkata – 700 001
Telephone:+91-33-22315718

8. Approved Re-appointment of Mr. Kishan Singh (DIN: 07526266) as Whole Time Director of the Company to hold office for the second term of Five (5) consecutive years w.e.f. 02/12/2022 to 01/12/2027 subject to approval of Shareholders in the ensuing Annual General Meeting.

Pursuant to the SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, their brief profiles of Directors seeking re-appointment are enclosed herewith. Further Pursuant to SEBI directions dated 14 June 2018 and based on the declarations received, we are to affirm that none of the above directors is debarred from holding the office of Director by virtue of any SEBI order or any other authority and therefore, they are not disqualified to be re-appointed as Directors of the Company.

9. The undertaking of non-applicability of Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 is enclosed herewith- **Annexure-2**.

The Company would be publishing Extract of Unaudited Financial Result for the 01st Quarter ended 30-06-2022, in accordance with Regulation 47(1) (b) of the SEBI (LODR) Regulations, 2015.

This information is also available on Company's website: www.adinathbio.com and on the stock exchange website: www.cse-india.com.

Request you to kindly take the above on record.

Thanking you,

Yours faithfully,

For Adinath Bio-Labs Limited

Kishan Singh
(Whole-Time Director)
(DIN: 07526266)

Encl.: As above.

CC:


To,
National Securities Depository Limited
4th Floor, 'A' Wing, Trade World,
Kamala Mills Compound,
Senapati Bapat Marg, Lower Parel
MUMBAI - 400 013

To,
Central Depository Services (India) Limited
Marathon Futurex, A-Wing,
25th Floor, Mafatlal Mills Compound,
N M Joshi Marg, Lower Parel (East)
MUMBAI - 400 013

To,
Adroit Corporate Services Pvt. Ltd
19/20, JaferbhoyIndl. Estate,
Makwana Road, Marol Naka,
Andheri (E), Mumbai – 400059

The disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015 is as follows:


| Details of events the need to be provided | Information of such event for Mr. Shri Prakash (DIN: 007526354) | Information of such event(s) for Mr. Kishan Singh (DIN:07526266) |
|---|--|--|
| Reason for change viz. appointment, resignation, removal, death or otherwise; | Re-appointment as a Non-Executive Director who retires by rotation in terms of Section 152 Companies Act, 2013 | Re-appointment as Whole Time Director of the Company for a term of five years starting from 02/12/2022 to 01/12/2027. |
| Date of Appointment/cessation (as applicable) & term of Appointment | The Board of Directors of the Company at its meeting held on today i.e 30 th July 2022 approved the re-appointment of Mr. Shri Prakash as Non-Executive Director who retires by rotation which is subject to approval of the shareholders in the ensuing AGM. | The Board of Directors of the Company at its meeting held on today i.e 30 th July 2022 approved the re-appointment of Mr. Kishan Singh as Whole Time Director. The tenure of the reappointment will be for a period of 5 years w.e.f 02/12/2022 to 01/12/2027 which is subject to approval of the shareholders in the ensuing AGM. |
| Brief Profile (in case of appointment) | He is having wide experience in the field of Marketing. | He is having wide experience in the field of Accounts, Finance and Taxation etc. |
| Disclosure of relationship between directors (in case of appointment of director) | Not related to any Director of the Company. | Not related to any Director of the Company. |
| Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 | Mr. Shri Prakash is not debarred from holding the office of director by virtue of any SEBI order or any other such authority | Mr. Kishan Singh is not debarred from holding the office of director by virtue of any SEBI order or any other such authority |



| Adinath Bio-Labs Limited | | | | | |
|---|---|---------------|---------------------------------|----------------|-----------------|
| CIN: L24230WB1982PLC034492 | | | | | |
| Statement of Standalone Unaudited Financial Results for the 1st Quarter ended 30th June, 2022 | | | | | |
| (Rs. In lakhs except FV and EPS) | | | | | |
| Sl. No. | Particulars | Quarter Ended | | Year ended | |
| | | Unaudited | Audited | Unaudited | Audited |
| | | 30-06-2022 | 31-03-2022 (Refer note no.5) | 30-06-2021 | 31-03-2022 |
| 1 | Income from operations | | | | |
| | (a) Net Sales / income from operations | - | - | - | - |
| | (b) Other Income | 8.49 | 4.05 | 0.63 | 5.32 |
| | Total income from operations (net) | 8.49 | 4.05 | 0.63 | 5.32 |
| 2 | Expenses | - | - | - | - |
| | (a) Changes in inventories of finished goods, work-in-progress and stock- in-trade | - | - | - | - |
| | (b) Employee benefits expense | 1.35 | 1.36 | 1.36 | 5.43 |
| | (c) Finance Cost | - | - | - | - |
| | (d) Depreciation and amortisation expense | 0.00 | 0.00 | 0.00 | 0.01 |
| | (e) Other expenses | 2.64 | 1.30 | 2.53 | 5.59 |
| | Total expenses | 3.99 | 2.66 | 3.89 | 11.03 |
| 3 | Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2) | 4.50 | 1.39 | (3.26) | (5.71) |
| 4 | Exceptional & Extraordinary Items | - | - | 48.91 | 99.91 |
| 5 | Profit / (Loss) before Tax (3 ± 4) | 4.50 | 1.39 | (52.17) | (105.63) |
| 6 | Tax expense | - | - | - | - |
| | Current Tax | - | - | - | - |
| | Deferred Tax | - | - | - | - |
| | Earlier Years | - | - | - | - |
| | Total Tax Expenses | - | - | - | - |
| 7 | Net Profit/(Loss) after tax(5 ± 6) | 4.50 | 1.39 | (52.17) | (105.63) |
| 8 | Other Comprehensive Income / (Loss) | - | - | - | - |
| 9 | Total Comprehensive Income / (Loss) (7 ± 8) | 4.50 | 1.39 | (52.17) | (105.63) |
| # | Paid-up equity share capital | 2,207.43 | 2,207.43 | 2,207.43 | 2,207.43 |
| | (Face Value of the Share shall be indicated in Re.) | 1 | 1 | 1 | 1 |
| # | Earnings Per Share (not annualised except for year ended): | | | | |
| | Basic & Diluted | 0.00 | | (0.02) | (0.05) |

Notes:

- 1 The above Unaudited Financial results have been reviewed by the Audit committee at their meeting and adopted by the Board of Directors at their meeting held on 30th July, 2022.
- 2 The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 3 The company is engaged in the business of Trading and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- 4 The Statutory Auditors of the Company have conducted a limited review of the above standalone unaudited financial results of the Company for the quarter ended June 30, 2022 and issued an unqualified report in this behalf.
- 5 The figures for the quarter ended 31st March, 2022, are the balancing figures between audited figures in respect of the full financial year ended 31st March, 2022 and the year to date figures upto the third quarter of financial year 2021-22.
- 6 Previous period's figures corresponding to current period are converted into lakhs.
- 7 Provisions for taxatious will be made at the end of the year.
- 8 Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.



Kishan Singh
Whole Time Director

DIN :07526266

Date: 30th July, 2022

Place: Kolkata

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Adinath Bio-Labs Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Adinath Bio-Labs Limited** (the "Company") for the 01st quarter ended on 30th June, 2022, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KSA & Co.

Chartered Accountants

FRN: 003822C


Kamal Piyush

Partner

Membership No.: 083399

UDIN: 22083399ANXJZY2481

Place: New Delhi

Date: July 30, 2022

Annexure 2

Date: 30th July, 2022

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,

Sub: Non- applicability of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) on a quarterly basis for public issue, rights issue, preferential issue etc..-

- (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;
- (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. Kishan Singh, Whole Time Director of Adinath Biolabs Limited hereby certify that Compliances of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company, as the company has not issued any share by way of public issue, right issue, preferential issue etc. during the quarter ended on 30th June, 2022.

You are requested to take the above information in your records.

Thanking you,
Yours faithfully,
For Adinath Bio-Labs Limited



Kishan Singh
(Whole-Time Director)
DIN: 007526266